Literature DB >> 16215810

Metastatic tumors of the nervous system.

Sophie Taillibert, Jean-Yves Delattre.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16215810     DOI： 10.1007/s11060-004-8092-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  8 in total

1.  Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

Authors:  Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

2.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

3.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

4.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

Review 5.  Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?

Authors:  T Siegal
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

6.  Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment.

Authors:  E Shmueli; N Wigler; M Inbar
Journal:  Eur J Cancer       Date:  2004-02       Impact factor: 9.162

7.  The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.

Authors:  Rose Lai; Chau T Dang; Mark G Malkin; Lauren E Abrey
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

8.  Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

Authors:  A J Clayton; S Danson; S Jolly; W D J Ryder; P A Burt; A L Stewart; P M Wilkinson; R S Welch; B Magee; G Wilson; A Howell; A M Wardley
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640
  8 in total
  2 in total

1.  Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy.

Authors:  M Maschio; L Dinapoli; S Gomellini; V Ferraresi; F Sperati; A Vidiri; P Muti; B Jandolo
Journal:  J Neurooncol       Date:  2009-11-24       Impact factor: 4.130

2.  Brain metastases admissions in Sweden between 1987 and 2006.

Authors:  K E Smedby; L Brandt; M L Bäcklund; P Blomqvist
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.